RESTEM Announces First-Patient-Dosed in the Phase I/IIa Study of Restem-L in Facioscapulohumeral Muscular Dystrophy

RESTEM announced the initiation of a Phase I/IIa study of Restem-L, the company’s umbilical lining modified progenitor cells off-the-shelf platform, for the treatment of facioscapulohumeral muscular dystrophy.